Jennifer Wilson

Dr. Jennifer Wilson

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
AZAyesha Zahid
Ayesha Zahid
HIHazrat Ismail
Hazrat Ismail
JWJennifer Wilson
Jennifer Wilson
DGDarren Grice
Darren Grice
Outer-membrane vesicles (OMVs), naturally secreted by Gram-negative bacteria, have gained recognition as a versatile platform for the development of next-generation vaccines. OMVs are essential contributors to bacterial pathogenesis, horizontal gene transfer, cellular communication, the maintenance of bacterial fitness, and quorum sensing. Their intrinsic immunogenicity, adjuvant properties, and scalability establish OMVs as potent tools for combating infectious diseases and cancer. Recent advancements in genetic engineering and biotechnology have further expanded the utility of OMVs, enabling the incorporation of multiple epitopes and antigens from diverse pathogens. These developments address critical challenges such as antigenic variability and co-infections, offering broader immune coverage and cost-effective solutions. This review explores the unique structural and immunological properties of OMVs, emphasizing their capacity to elicit robust immune responses. It critically examines established and emerging engineering strategies, including the genetic engineering of surface-displayed antigens, surface conjugation, glycoengineering, nanoparticle-based OMV engineering, hybrid OMVs, and in situ OMV production, among others. Furthermore, recent advancements in preclinical research on OMV-based vaccines, including synthetic OMVs, OMV-based nanorobots, and nanodiscs, as well as emerging isolation and purification methods, are discussed. Lastly, future directions are proposed, highlighting the potential integration of synthetic biology techniques to accelerate research on OMV engineering.

1 January 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JWJennifer Wilson
Jennifer Wilson
ALAndrew Elohim Laloo
Andrew Elohim Laloo
SSSanjesh Singh
Sanjesh Singh
Vito FerroVito Ferro
Vito Ferro

31 January 2022 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
MCMohit Chhabra
Mohit Chhabra
JWJennifer Wilson
Jennifer Wilson
LWLiang Wu
Liang Wu
GDGideon J. Davies
Gideon J. Davies
NGNeha S Gandhi
Neha S Gandhi
Vito FerroVito Ferro
Vito Ferro
Pixatimod (PG545), a heparan sulfate (HS) mimetic and anticancer agent currently in clinical trials, is a potent inhibitor of heparanase. Heparanase is an endo‐β‐glucuronidase that degrades HS in the extracellular matrix and basement membranes and is implicated in numerous pathological processes such as cancer and viral infections, including SARS−CoV‐2. To understand how PG545 interacts with heparanase, we firstly carried out a conformational analysis through a combination of NMR experiments and molecular modelling which showed that the reducing end β‐D‐glucose residue of PG545 adopts a distorted conformation. This was followed by docking and molecular dynamics simulations to study the interactions of PG545 with heparanase, revealing that PG545 is able to block the active site by binding in different conformations, with the cholestanol side‐chain making important hydrophobic interactions. While PG545 blocks its natural substrate HS from binding to the active site, small synthetic heparanase substrates are only partially excluded, and thus pentasaccharide or larger substrates are preferred for assaying this class of inhibitor. This study provides new insights for the design of next‐generation heparanase inhibitors and substrates.

30 November 2010 in BMC Microbiology
Verified
Journal Article
Open access
ESEvgeny Semchenko
Evgeny Semchenko
CDChristopher Day
Christopher Day
JWJennifer Wilson
Jennifer Wilson
DGDarren Grice
Darren Grice
AMAnthony P Moran
Anthony P Moran
Victoria KorolikVictoria Korolik
Victoria Korolik
Background: Campylobacter jejuni is a major bacterial cause of food-borne enteritis, and its lipooligosaccharide (LOS) plays an initiating role in the development of the autoimmune neuropathy, Guillain-Barré syndrome, by induction of anti-neural cross-reactive antibodies through ganglioside molecular mimicry. Results: Herein we describe the existence and heterogeneity of multiple LOS forms in C. jejuni strains of human and chicken origin grown at 37°C and 42°C, respectively, as determined on sodium dodecyl sulphate-polyacrylamide electrophoresis gels with carbohydrate-specific silver staining and blotting with anti-ganglioside ligands, and confirmed by nuclear magnetic resonance (NMR) spectroscopy. The C. jejuni NCTC 11168 original isolate (11168-O) was compared to its genome-sequenced variant (11168-GS), and both were found to have a lower-Mr LOS form, which was different in size and structure to the previously characterized higher-Mr form bearing GM1 mimicry. The lower-Mr form production was found to be dependent on the growth temperature as the production of this form increased from ~5%, observed at 37°C to ~35% at 42°C. The structure of the lower-Mr form contained a β-D-Gal-(1→3)-β-D-GalNAc disaccharide moiety which is consistent with the termini of the GM1, asialo-GM1, GD1, GT1 and GQ1 gangliosides, however, it did not display GM1 mimicry as assessed in blotting studies but was shown in NMR to resemble asialo-GM1. The production of multiple LOS forms and lack of GM1 mimicry was not a result of phase variation in the genes tested of NCTC 11168 and was also observed in most of the human and chicken isolates of C. jejuni tested. Conclusion: The presence of differing amounts of LOS forms at 37 and 42°C, and the variety of forms observed in different strains, indicate that LOS form variation may play a role in an adaptive mechanism or a stress response of the bacterium during the colonization of different hosts.

27 March 2007 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
IPIan R. Peak
Ian R. Peak
DGDarren Grice
Darren Grice
IFIsabelle Faglin
Isabelle Faglin
ZKZoran Klipic
Zoran Klipic
PCPatrick Collins
Patrick Collins
JWJennifer Wilson
Jennifer Wilson
The glycosyltransferase enzymes (Lgts) responsible for the biosynthesis of the lipooligosaccharide‐derived oligosaccharide structures from Moraxella catarrhalis have been investigated. This upper respiratory tract pathogen is responsible for a spectrum of illnesses, including otitis media (middle ear infection) in children, and contributes to exacerbations of chronic obstructive pulmonary disease in elderly patients. To investigate the function of the glycosyltransferase enzymes involved in the biosynthesis of lipooligosaccharide of M. catarrhalis and to gain some insight into the mechanism of serotype specificity for this microorganism, mutant strains of M. catarrhalis were produced. Examination by NMR and MS of the oligosaccharide structures produced by double‐mutant strains (2951lgt1/4Δ and 2951lgt5/4Δ) and a single‐mutant strain (2951lgt2Δ) of the bacterium has allowed us to propose a model for the serotype‐specific expression of lipooligosaccharide in M. catarrhalis. According to this model, the presence/absence of Lgt4 and the Lgt2 allele determines the lipooligosaccharide structure produced by a strain. Furthermore, it is concluded that Lgt4 functions as an N‐acetylglucosylamine transferase responsible for the addition of an α‐d‐GlcNAc (1→2) glycosidic linkage to the (1→4) branch, and also that there is competition between the glycosyltransferases Lgt1 and Lgt4. That is, in the presence of an active Lgt4, GlcNAc is preferentially added to the (1→4) chain of the growing oligosaccharide, instead of Glc. In serotype B strains, which lack Lgt4, Lgt1 adds a Glc at this position. This implies that active Lgt4 has a much higher affinity/specificity for the β‐(1→4)‐linked Glc on the (1→4) branch than does Lgt1.

1 November 2006 in Carbohydrate Research
Verified
Journal Article
Closed access
JWJennifer Wilson
Jennifer Wilson
PCPatrick Collins
Patrick Collins
ZKZoran Klipic
Zoran Klipic
DGDarren Grice
Darren Grice
IPIan R. Peak
Ian R. Peak